StreetInsider.com News Articles

Form 4 CARLSMED, INC. For: Sep 08 Filed by: Bertolini Jeffrey

Thu, 10 Sep 2026 18:38:00 -0400

si-local-file:///var/storage/secattach/20260910/27049683.html

Form 3 CARLSMED, INC. For: Sep 08 Filed by: Bertolini Jeffrey

Thu, 10 Sep 2026 18:37:00 -0400

si-local-file:///var/storage/secattach/20260910/27049676.html

Form EFFECT CARLSMED, INC.

Mon, 24 Aug 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260824/26963759.html

Form EFFECT CARLSMED, INC.

Mon, 24 Aug 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260824/26963759.html

Form S-3 CARLSMED, INC.

Fri, 14 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260814/26930551.html

Form S-3 CARLSMED, INC.

Fri, 14 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260814/26930551.html

Carlsmed Inc (CARL) PT Raised to $20 at Truist Securities

Thu, 06 Aug 2026 05:10:39 -0400

Truist Securities analyst Richard Newitter raised the price target on Carlsmed Inc (NASDAQ: CARL) to $20.00 (from $18.00) while maintaining a Buy rating.

The analyst comments "CARL delivered a 2Q beat & raise, with upside highlighted by 57% rev growth, >60% trained surgeon growth, and ~110bps of GM upside. The FY26 guide moved up by more than the beat, and the FY27 IPPS final rule (7/31) is now in hand, locking in enhanced aprevo lumbar reimbursement, effective 10/1. We think CARL remains well-positioned for beats and raises given: (1) new DRGs bolstering hosp. economics into 2027, (2) an 'asset-light' model scaling

Carlsmed Inc (CARL) PT Raised to $20 at Truist Securities

Thu, 06 Aug 2026 05:10:39 -0400

Truist Securities analyst Richard Newitter raised the price target on Carlsmed Inc (NASDAQ: CARL) to $20.00 (from $18.00) while maintaining a Buy rating.

Form 10-Q CARLSMED, INC. For: Jun 30

Wed, 05 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260805/26874404.html

Form 10-Q CARLSMED, INC. For: Jun 30

Wed, 05 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260805/26874404.html

Form 8-K CARLSMED, INC. For: Aug 05

Wed, 05 Aug 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260805/26873937.html

Form 8-K CARLSMED, INC. For: Aug 05

Wed, 05 Aug 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260805/26873937.html

Carlsmed® Reports Second Quarter 2026 Financial Results and Raises Full-Year Guidance

Wed, 05 Aug 2026 16:01:00 -0400

Second quarter 2026 revenue of $18.9 million, representing 57% growth year-over-year

Full year 2026 revenue guidance raised to $74 million to $78 million

CARLSBAD, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today reported financial results for the second quarter ended June 30, 2026.

“Our second quarter 2026 results reflect the growing momentum of aprevo^® procedures and further progress on our path to profitability,” said Mike Cordonnier, Chairman and Chief Executive Officer. "We

Carlsmed® Reports Second Quarter 2026 Financial Results and Raises Full-Year Guidance

Wed, 05 Aug 2026 16:01:00 -0400

Second quarter 2026 revenue of $18.9 million, representing 57% growth year-over-year

Full year 2026 revenue guidance raised to $74 million to $78 million

Carlsmed Announces Favorable Reimbursement for aprevo® lumbar Procedures

Mon, 03 Aug 2026 08:00:00 -0400

Centers for Medicare & Medicaid Services (CMS) Fiscal Year 2027 Inpatient Final Rule creates three new Medicare Severity-Diagnosis Related Groups (MS-DRGs), with favorable reimbursement for Carlsmed aprevo® Lumbar spine fusion procedures

CARLSBAD, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that the Centers for Medicare & Medicaid Services (CMS) has finalized a favorable reimbursement policy applicable to inpatient aprevo^® Lumbar spinal fusion procedures in the Hospital Inpatient Prospective Payment System (IPPS) Final Rule for fiscal year 2027 (FY27). The new

Carlsmed Announces Favorable Reimbursement for aprevo® lumbar Procedures

Mon, 03 Aug 2026 08:00:00 -0400

Carlsmed, Inc. To Participate in Upcoming Investor Conferences

Mon, 27 Jul 2026 16:01:00 -0400

CARLSBAD, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions today announced that management will participate in the following investor conferences:

11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference. The Company will host one-on-one meetings on Monday, August 10, 2026.
Bank of America SMID Cap Virtual Conference. Fireside chat on Wednesday, August 12, 2026, at 11:00 AM ET. A live webcast will be available to registered participants. Investors interested in participating in virtual one-on-one meetings

Carlsmed, Inc. To Participate in Upcoming Investor Conferences

Mon, 27 Jul 2026 16:01:00 -0400

11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference. The Company will host one-on-one meetings on Monday, August 10, 2026.
Bank of America SMID Cap Virtual Conference. Fireside chat on Wednesday, August 12, 2026, at 11:00 AM ET. A live webcast will be available to registered participants. Investors interested in participating in virtual one-on-one meetings

Carlsmed Inc. to Report Second Quarter 2026 Financial Results on August 5, 2026

Wed, 22 Jul 2026 16:01:00 -0400

CARLSBAD, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced it will report its second quarter 2026 financial results after market close on Wednesday, August 5, 2026. Management will also host a conference call and concurrent webcast starting at 1:30 PM Pacific Time.

A live webcast of the conference call will be available in the Events & Presentations section of the company’s investor website at investors.carlsmed.com. Participants may also join via

Carlsmed Inc. to Report Second Quarter 2026 Financial Results on August 5, 2026

Wed, 22 Jul 2026 16:01:00 -0400

A live webcast of the conference call will be available in the Events & Presentations section of the company’s investor website at investors.carlsmed.com. Participants may also join via

Carlsmed Inc. to Report Second Quarter 2026 Financial Results on August 5, 2026

Wed, 22 Jul 2026 16:01:00 -0400

A live webcast of the conference call will be available in the Events & Presentations section of the company’s investor website at investors.carlsmed.com. Participants may also join via

Carlsmed Inc. to Report Second Quarter 2026 Financial Results on August 5, 2026

Wed, 22 Jul 2026 16:01:00 -0400

A live webcast of the conference call will be available in the Events & Presentations section of the company’s investor website at investors.carlsmed.com. Participants may also join via

Piper Sandler's Spine Doc Survey Results: 'We favor ATEC and GMED as our top picks'

Thu, 09 Jul 2026 10:30:40 -0400

Piper Sandler analyst Matt O'Brien weighs in on the spine space following the Spine Doc Survey.

The analyst commented: "We surveyed 30 spine surgeons that perform at least 75 cases annually and were very pleased to hear a high majority of them say procedure volumes have been steady the past three months and the outlook for the remainder of the year is positive too. They expect to perform more robotically-assisted cases in the future, with GMED and MDT the standouts here. Feedback on the new MDT robot was really good, which is a clear positive for them, and a number of

Piper Sandler's Spine Doc Survey Results: 'We favor ATEC and GMED as our top picks'

Thu, 09 Jul 2026 10:30:40 -0400

Piper Sandler analyst Matt O'Brien weighs in on the spine space following the Spine Doc Survey.

Piper Sandler's Spine Doc Survey Results: 'We favor ATEC and GMED as our top picks'

Thu, 09 Jul 2026 10:30:40 -0400

Piper Sandler analyst Matt O'Brien weighs in on the spine space following the Spine Doc Survey.